RVL Pharmaceuticals plc

:OSMT   4:00:00 PM EDT
-0.06 (-5.56%)

Adamas Pharmaceuticals Announces Adamas Will Acquire Global Rights To Osmolex Er For $7.5 Mln

Published: 12/02/2020 12:22 GMT
(OSMT) - Adamas Announces Agreement to Settle Patent Litigation With Osmotica.
Adamas Pharmaceuticals Inc - Adamas Will Acquire Global Rights to Osmolex Er for $7.5 Million.
Adamas Pharmaceuticals - As Result of Agreement, Both Parties Will Drop Their Respective Claims Relating to Patent Litigation.
Adamas Pharmaceuticals Inc - Will Receive Existing Inventory and All Rights to Osmolex Er.
Adamas Pharmaceuticals Inc - Entered a Supply Agreement in Which Osmotica Will Be Sole Manufacturer of Osmolex Er.